A Clinical Case of MOGAD

 

 Buy Article Permissions and Reprints

Background

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is a demyelinating inflammatory disease of the central nervous system (CNS). It is characterized by the presence of anti-MOG antibodies and a core clinical demyelinating event such as optic neuritis or transverse myelitis. The clinical spectrum of this disease includes optic neuritis, transverse myelitis encephalopathy, and seizures. Optic neuritis is the most frequent presentation at time of diagnosis. The disease can be relapsing/remitting [1]. It can start in all age groups, but the average age is 30 years old [2].

Publication History

Received: 29 October 2023

Accepted: 22 January 2024

Article published online:
23 April 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• References

• 1 Sechi E, Cacciaguerra L, Chen JJ. et al. Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Front Neurol 2022; 13: 885218
  CrossrefPubMedGoogle Scholar
• 2 Hor JY, Fujihara K. Epidemiology of myelin oligodendrocyte glycoprotein antibody-associated diseas: a review of prevalence and incidence worldwide. Front Neurol 2023; 14: 1260358
  CrossrefPubMedGoogle Scholar
• 3 Gupta S, Sethi P, Duvesh RK. et al. Optic perineuritis. BMJ Open Ophthalmol 2021; 6: 745
  CrossrefPubMedGoogle Scholar
• 4 Abel A, McClelland C, Lee MS. Critical review: Typical and atypical optic neuritis. Surv Ophthalmol 2019; 64: 770-779
  CrossrefPubMedGoogle Scholar
• 5 Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): Clinical features and diagnosis – UpToDate [Internet]. Accessed January 24, 2024 at: https://www.uptodate.com/contents/myelin-oligodendrocyte-glycoprotein-antibody-associated-disease-mogad-clinical-features-and-diagnosis%23H774067702
  PubMedGoogle Scholar